Document is current

Article History

Received: 13 January 2026

Accepted: 15 May 2026

First Online: 29 May 2026

Ethics

Competing interests: R.U. reports consultancy for Bristol Meyers Squibb and speaker fee for educational events from Otuska and Viatris outside of the current work. T.P. has received speaker or consultancy fees from Boehringer Ingelheim, Bristol Myers Squibb, CNX Therapeutics, Janssen, Lecturing Minds Stockholm AB, Lundbeck, Otsuka, Recordati, ROVI Biotech, Schwabe Pharma, Sunovion, and Teva Pharmaceuticals; he receives book royalties from Wiley Blackwell; and he co-directs a company that designs digital resources to support treatment of mental illness. B.I.P. is founder of the PsyMetRiC Operating Division in partnership with University of Birmingham Enterprise, but does not receive any direct personal financial benefit. B.I.P. is Topic Advisor for Severe and Enduring Mental Illness for the National Institute for Health and Care Excellence (NICE). B.I.P. is a member of the Digital Mental Health A.I. Airlock Governance Board for the Medicines and Healthcare products Regulatory Agency (MHRA). P.A.L. has received honoraria for talks presented at educational meetings organized by Boehringer Ingelheim outside of the submitted work reports being a Director and shareholder of Celentyx Ltd although these associations are outside the current work.